Biomarker to Predict High-risk Clinical Outcomes for Colon, Lung, and Ovarian Cancers
Posted May 08 2012 8:00pm
Description of Invention: It has long been known that general genomic instability is associated with cancer. NIH scientists Drs. Habermann and Reid at the National Cancer Institute, along with West Virginia University scientists Drs. Mettu and Guo, have recently identified specific genes whose instability is strongly associated with poor outcomes for colon, small-cell lung, and ovarian cancers. Using this 12-gene genomic instability signature as a biomarker could be diagnostic tool for identifying high-risk patients that would benefit from more aggressive forms of treatment.
Applications: Diagnostic tool for identifying patients at high-risk for developing colon, small-cell lung, and ovarian cancers that are recurring and/or aggressive.
Allows more accurate prognoses by separating high-risk from low-risk cancer patient populations.
Allows doctors to choose more individualized therapies for patients based on whether the cancer is at high or low risk for aggressiveness or recurrence.
For Licensing Information Please Contact: Surekha Vathyam Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-4076 Fax: 301-402-0220